Cases & Deals

  • Home
  • Practices
  • Sumitovant Biopharma acquires remaining stake in Urovant Sciences

Share

Sumitovant Biopharma acquires remaining stake in Urovant Sciences

March 2021

Client(s) Sumitomo Dainippon Pharma

Jones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash. Sumitovant previously owned 72% of the outstanding shares of Urovant common stock. The acquisition consideration represents an equity value for Urovant of $584 million and an enterprise value of $681 million. Upon closing, Urovant became a wholly owned subsidiary of Sumitovant and Urovant’s common stock ceased trading on the Nasdaq stock market.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.